Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).
Publication
, Journal Article
Mato, AR; Davids, MS; Sharman, J; Roeker, LE; Kay, N; Kater, AP; Rogers, K; Thompson, MC; Rhodes, J; Goy, A; Skarbnik, A; Schuster, SJ ...
Published in: Clin Cancer Res
February 15, 2022
The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Cancer Res
DOI
EISSN
1557-3265
Publication Date
February 15, 2022
Volume
28
Issue
4
Start / End Page
603 / 608
Location
United States
Related Subject Headings
- Protein Kinase Inhibitors
- Phosphatidylinositol 3-Kinases
- Oncology & Carcinogenesis
- Leukemia, Lymphocytic, Chronic, B-Cell
- Immunotherapy
- Humans
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., … Woyach, J. A. (2022). Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res, 28(4), 603–608. https://doi.org/10.1158/1078-0432.CCR-21-1237
Mato, Anthony R., Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, et al. “Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).” Clin Cancer Res 28, no. 4 (February 15, 2022): 603–8. https://doi.org/10.1158/1078-0432.CCR-21-1237.
Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, et al. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 Feb 15;28(4):603–8.
Mato, Anthony R., et al. “Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).” Clin Cancer Res, vol. 28, no. 4, Feb. 2022, pp. 603–08. Pubmed, doi:10.1158/1078-0432.CCR-21-1237.
Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O’Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 Feb 15;28(4):603–608.
Published In
Clin Cancer Res
DOI
EISSN
1557-3265
Publication Date
February 15, 2022
Volume
28
Issue
4
Start / End Page
603 / 608
Location
United States
Related Subject Headings
- Protein Kinase Inhibitors
- Phosphatidylinositol 3-Kinases
- Oncology & Carcinogenesis
- Leukemia, Lymphocytic, Chronic, B-Cell
- Immunotherapy
- Humans
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis